Form 8-K - Current report:
SEC Accession No. 0001193125-26-000968
Filing Date
2026-01-02
Accepted
2026-01-02 16:30:26
Documents
11
Period of Report
2025-12-30
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eldn-20251230.htm   iXBRL 8-K 48652
2 EX-4.1 eldn-ex4_1.htm EX-4.1 134345
  Complete submission text file 0001193125-26-000968.txt   311942

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eldn-20251230.xsd EX-101.SCH 24852
13 EXTRACTED XBRL INSTANCE DOCUMENT eldn-20251230_htm.xml XML 4703
Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36620 | Film No.: 26502782
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)